U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
NOTIFICATION OF LATE FILING
FORM 12b-25
SEC File Number 2-89332 Cusip Number
- ------------------------- ----------------------
[Check One]
|_| Form 10-K and Form 10-KSB |_| Form 20-F |_| Form 11-K |X| Form 10-Q and Form
10-QSB |_| Form N-SAR
For the Period Ended: September 30, 2002
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended
Read Attached Instruction Sheet Before Preparing Form. Please Print
or Type.
Nothing in this form shall be constructed to imply that the
Commission has verified any information contained herein
If the notification relates to a portion of the filing checked
above, identify the Item[s] to which the notification relates:
PART I - REGISTRANT INFORMATION
Full Name of Registrant: Interferon Sciences Research Partners, Ltd.
Former Name if Applicable:
Address of Principal Executive Office [Street and Number]:
783 Jersey Avenue
New Brunswick, New Jersey 08901
City, State and Zip Code
PART II - RULES 12b-25[b] and [c]
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25[b], the following should
be completed.
[Check box if appropriate]
[a] The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expenses;
[X] [b] The subject annual report, semi-annual report, transition report
on Form 10-K, Form 20-F, Form 11-K, or form N-SAR, or portion thereof
will be filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report or transition
report on Form 10- Q, or portion thereof will be filed on or before
the fifth calendar day following the prescribed due date; and
[c] The accountant's statement or other exhibit required by Rule 12b-25[c]
has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why Form 10-K and Form 10-KSB,
20-F, 11-K, 10-Q, or N-SAR, or the transition report or portion thereof could
not be filed within the prescribed time period.
The registrant is unable to finalize its Form 10-Q until Interferon Sciences,
Inc.'s Form 10-Q is finalized, which is expected to occur by November 19, 2002.
PART IV - OTHER INFORMATION
[1] Name and telephone number of person to contact in regard to this
notification
Lawrence M. Gordon (732) 249-3250
[Name] [Area Code] [Telephone No.]
[2] Have all other periodic reports required under section 13 or 15[d] of
the Securities and Exchange Act of 1934 or section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter
period that the registrant was required to file such report[s] been
filed? If answer is no, identify report[s]. [ X ] Yes [ ] No
[3] Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or
portion thereof? [ ] Yes [ X ] No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
Interferon Sciences Research Partners, Ltd.
[Name of Registrant as Specified in Charter]
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: November 14, 2002 By: /s/ Samuel H. Ronel, Ph.D.
- --------------------------- --------------------------
Samuel H. Ronel, President
INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
[other than an executive officer], evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute
Federal Criminal Violation [See 18 U.S.C. 1001]
GENERAL INSTRUCTIONS
1. This form is required by Rule 12b-25 [17 CFR 240.12b-25] of the General
Rules and Regulations under the Securities Exchange Act of 1934.
2. One signed original and four conformed copies of this form and amendments
thereto must be completed and filed with the Securities and Exchange
Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the
General Rules and Regulations under the Act. The information contained in or
filed with the Form will be made a matter of the public record in the
Commission files.
3. A manually signed copy of the form and amendments thereto shall be filed
with each national securities exchange on which any class of securities of
the registrant is registered.
4 Amendments to the notifications must also be filed on form 12b-25, but need
not restate information that has been correctly furnished. The form shall be
clearly identified as an amendment notification.
5. Electronic Filers - This form shall not be used by electronic filers unable
to timely file a report solely due to electronic difficulties. Filers unable
to submit a report within the time period prescribed due to difficulties in
electronic filing should comply with either Rule 201 or Rule 202 of
Regulation S-T or apply for an adjustment in filing date pursuant to Rule
13(b) of Regulation S-T.